516 related articles for article (PubMed ID: 29114832)
1. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
2. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
3. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
4. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
5. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
[TBL] [Abstract][Full Text] [Related]
6. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
7. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
8. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
Stobaugh DJ; Deepak P
Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
[TBL] [Abstract][Full Text] [Related]
9. Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor.
Meyer A; Taine M; Drouin J; Weill A; Carbonnel F; Dray-Spira R
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1269-1281.e9. PubMed ID: 34298191
[TBL] [Abstract][Full Text] [Related]
10. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
[TBL] [Abstract][Full Text] [Related]
11. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
12. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
Thomsen SB; Ungaro RC; Allin KH; Elmahdi R; Poulsen G; Andersson M; Colombel JF; Jess T
Aliment Pharmacol Ther; 2022 May; 55(9):1128-1138. PubMed ID: 35080036
[TBL] [Abstract][Full Text] [Related]
13. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
Kirchgesner J; Nyboe Andersen N; Carrat F; Jess T; Beaugerie L;
Gut; 2020 May; 69(5):852-858. PubMed ID: 31446428
[TBL] [Abstract][Full Text] [Related]
14. Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Diseases Receiving Treatment With Thiopurines.
Khan N; Lee H; Trivedi C; Kavani H; Medvedeva E; Xie D; Lewis JD; Yang YX
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2262-2268. PubMed ID: 30853615
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
Meyer A; Drouin J; Weill A; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2021 Aug; 54(3):302-311. PubMed ID: 34162011
[TBL] [Abstract][Full Text] [Related]
16. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
17. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
[TBL] [Abstract][Full Text] [Related]
18. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
19. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease.
Nyboe Andersen N; Pasternak B; Basit S; Andersson M; Svanström H; Caspersen S; Munkholm P; Hviid A; Jess T
JAMA; 2014 Jun; 311(23):2406-13. PubMed ID: 24938563
[TBL] [Abstract][Full Text] [Related]
20. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
